Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of Albiglutide in Japanese T2DM patients
NCT01777282Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2013
- Primary completion
- Jan 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of albiglutide in type 2 diabetes mellitus (T2DM), sponsored by GSK. Started Feb 2013; status: completed.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01777282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01777282.